…
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-R
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Ideaya Biosciences is a clinical‑stage precision oncology company developing small‑molecule therapies that exploit synthetic lethality and DNA damage response (DDR) vulnerabilities. Long‑term growth may be supported by clinical trial readouts, biomarker‑directed patient selection and collaborations with larger biopharma partners that could aid development and commercialization, which may attract investors seeking exposure to DDR‑targeted oncology.
Main risks are high clinical and regulatory uncertainty, ongoing funding and dilution needs, and intense competition from larger oncology companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -113.70M | -274.48M | -112.96M | -58.66M | -49.76M |
| Net income | -113.70M | -274.48M | -112.96M | -54.81M | -47.53M |
| Selling general administrative | 63.32M | 39.30M | 28.31M | 23.90M | 20.05M |
| Gross profit | -95.99M | 3.17M | 19.38M | 50.93M | 27.94M |
| Reconciled depreciation | 4.59M | 3.83M | 4.01M | 2.10M | 1.73M |
| Ebit | -159.31M | -274.48M | -112.96M | -64.60M | -51.99M |
| Ebitda | -154.72M | -270.64M | -108.95M | -62.50M | -50.27M |
| Depreciation and amortization | 4.59M | 3.83M | 4.01M | 2.10M | 1.73M |
| Non operating income net other | - | - | - | 3.85M | 0.51M |
| Operating income | -159.31M | -326.98M | -134.43M | -62.50M | -50.27M |
| Other operating expenses | 378.02M | 333.98M | 157.81M | 113.43M | 78.21M |
| Interest expense | - | - | 21.47M | 3.85M | 0.51M |
| Interest income | 45.62M | 52.50M | 21.47M | 3.85M | 0.51M |
| Net interest income | 45.62M | 52.50M | 21.47M | 3.85M | 0.51M |
| Income tax expense | - | - | 3.84M | -3.85M | -2.23M |
| Total revenue | 218.71M | 7.00M | 23.39M | 50.93M | 27.94M |
| Total operating expenses | 63.32M | 330.14M | 153.81M | 113.43M | 78.21M |
| Cost of revenue | 314.70M | 3.83M | 4.01M | - | - |
| Total other income expense net | 45.62M | 52.50M | 21.47M | 3.85M | 0.51M |
| Net income from continuing ops | -113.70M | -274.48M | -112.96M | -58.66M | -49.76M |
| Net income applicable to common shares | - | - | - | -58.66M | -49.76M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1109.32M | 1124.09M | 649.32M | 387.97M | 381.35M |
| Other current assets | 21.37M | 13.39M | -632.61M | 5.41M | 3.12M |
| Total liab | 86.39M | 64.94M | 28.23M | 387.97M | 381.35M |
| Total stockholder equity | 1022.93M | 1059.15M | 621.09M | 349.45M | 301.51M |
| Other current liab | 40.89M | 30.35M | 18.76M | 17.00M | 12.32M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -736.54M | -622.84M | -348.36M | -235.40M | -176.75M |
| Other liab | - | - | - | 5.18M | 31.19M |
| Other assets | - | - | - | 0.20M | 0.40M |
| Cash | 112.83M | 84.38M | 157.02M | 68.63M | 92.05M |
| Total current liabilities | 58.81M | 46.07M | 27.10M | 31.72M | 45.16M |
| Current deferred revenue | - | - | - | 8.57M | 29.04M |
| Net debt | -84.91M | -65.21M | -154.15M | -65.15M | -86.86M |
| Short term debt | 0.34M | 0.30M | 1.75M | 1.87M | 1.70M |
| Short long term debt total | 27.91M | 19.17M | 2.87M | 3.48M | 5.18M |
| Other stockholder equity | 1757.20M | 1681.17M | 968.88M | 587.72M | 478.97M |
| Property plant equipment | - | - | - | 6.51M | 4.76M |
| Total current assets | 666.73M | 689.71M | 532.63M | 370.45M | 251.00M |
| Long term investments | 410.30M | 405.83M | 107.49M | 8.32M | 121.29M |
| Net tangible assets | - | - | - | 349.45M | 301.51M |
| Short term investments | 526.56M | 591.94M | 368.10M | 296.20M | 154.72M |
| Net receivables | 5.97M | 0.00M | 0.02M | 0.21M | 1.10M |
| Inventory | - | - | 532.61M | -8.32M | -121.29M |
| Accounts payable | 17.58M | 15.42M | 6.60M | 4.28M | 2.10M |
| Accumulated other comprehensive income | 2.27M | 0.81M | 0.56M | -2.87M | -0.71M |
| Common stock total equity | - | - | - | 0.01M | 0.00M |
| Retained earnings total equity | - | - | - | -235.40M | -176.75M |
| Non currrent assets other | 1.01M | 0.81M | 0.78M | 0.20M | 0.40M |
| Non current assets total | 442.60M | 434.38M | 116.68M | 17.52M | 130.35M |
| Capital lease obligations | 27.91M | 19.17M | 2.87M | 3.48M | 5.18M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 72.34M | -502.56M | -56.79M | -29.96M | -67.02M |
| Change to liabilities | - | - | - | 6.44M | 5.38M |
| Total cashflows from investing activities | 69.98M | -502.56M | -158.46M | -33.40M | -69.67M |
| Total cash from financing activities | 29.78M | 677.55M | 362.72M | 97.17M | 145.45M |
| Change to operating activities | - | - | - | 2.17M | 3.79M |
| Net income | -113.70M | -274.48M | -112.96M | -58.66M | -49.76M |
| Change in cash | 28.45M | -72.59M | 89.04M | -23.41M | 20.01M |
| Begin period cash flow | 84.38M | 157.78M | 68.74M | 92.15M | 72.14M |
| End period cash flow | 112.83M | 85.18M | 157.78M | 68.74M | 92.15M |
| Total cash from operating activities | -71.10M | -247.58M | -115.22M | -87.17M | -55.78M |
| Issuance of capital stock | 24.86M | 663.63M | 181.83M | 94.96M | 143.25M |
| Depreciation | 4.59M | 3.83M | 4.01M | 2.10M | 1.73M |
| Other cashflows from investing activities | 69.98M | - | - | - | - |
| Change to inventory | - | - | -2.28M | - | 3.79M |
| Change to account receivables | 0.00M | 0.01M | 0.19M | 0.89M | 0.77M |
| Sale purchase of stock | - | - | - | 88.31M | 88.19M |
| Other cashflows from financing activities | 29.78M | 23.32M | 52.95M | 2.20M | 2.20M |
| Change to netincome | - | - | - | 11.63M | 8.24M |
| Capital expenditures | 2.37M | 3.86M | 2.37M | 3.44M | 2.64M |
| Change receivables | - | - | - | 0.89M | 0.77M |
| Cash flows other operating | - | - | - | -48.88M | -23.96M |
| Cash and cash equivalents changes | - | - | - | -23.41M | 20.01M |
| Change in working capital | 1.87M | 11.55M | -13.21M | -41.55M | -17.81M |
| Stock based compensation | 46.12M | 34.75M | 18.49M | 11.63M | 8.24M |
| Other non cash items | -9.98M | -23.23M | -11.55M | -0.69M | 1.83M |
| Free cash flow | -73.47M | -251.44M | -117.59M | -90.62M | -58.42M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IDYA Ideaya Biosciences Inc |
-2.96 9.75% |
27.40 | - | 4.65 | 15.52 | 3.06 | 12.26 | -7.80 |
| NVO Novo Nordisk A/S |
-0.99 2.39% |
40.60 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.90 0.73% |
533.89 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
5.36 0.56% |
957.76 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-R
5000 Shoreline Court, South San Francisco, CA, United States, 94080
650 443 6209
145
| Name | Title | Year Born |
|---|---|---|
| Mr. Yujiro S. Hata | Co-Founder, CEO, Pres & Director | 1974 |
| Mr. Paul A. Stone | Sr. VP, CFO & Principal Accounting Officer | 1964 |
| Dr. Michael A. White Ph.D. | Sr. VP & Chief Scientific Officer | 1965 |
| Dr. Jeffrey Hager Ph.D. | Co -Founder | 1964 |
| Mr. Andres Ruiz Briseno CPA | VP and Head of Bus. Operations & IR | 1986 |
| Mr. Jason S. Throne J.D., Esq. | Sr. VP, Gen. Counsel & Company Sec. | 1972 |
| Dr. Paul A. Barsanti Ph.D. | Sr. VP & Head of Drug Discovery | NA |
| Dr. Matthew Maurer M.D. | VP and Head of Medical Affairs & Clinical Oncology | NA |
| Mr. Mick O'Quigley | Sr. VP of Devel. Operations | NA |
| Dr. Darrin M. Beaupre M.D., Ph.D. | Sr. VP & Chief Medical Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.